Sacubitril

Sacubitril
Clinical data
Other names	AHU-377
License data	EU EMA: by INN;
ATC code	C09DX04 (WHO) (combination with valsartan);
Identifiers
	IUPAC name 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid;
CAS Number	149709-62-6 ;
PubChem CID	9811834;
DrugBank	DB09292;
ChemSpider	7987587;
UNII	17ERJ0MKGI;
KEGG	D10225;
CompTox Dashboard (EPA)	DTXSID20164370 ;
Chemical and physical data
Formula	C24H29NO5
Molar mass	411.498 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O;
	InChI InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m1/s1; Key:PYNXFZCZUAOOQC-UTKZUKDTSA-N;

Sacubitril (/səˈkjuːbɪtrɪl/; INN) is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure.^[1] It was approved under the FDA's priority review process for use in heart failure on July 7, 2015.

^ Cite error: The named reference McMurray was invoked but never defined (see the help page).

[McMurray-1] Cite error: The named reference McMurray was invoked but never defined (see the help page).

[1]